Setanaxib

Phase 2Small molecule

CCalliditas Therapeutics Suisse SA

Setanaxib is one of 85 small molecule programs targeting Primary Biliary Cholangitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Biliary CholangitisActive, not recruiting

Alport SyndromeActive, not recruiting

Squamous Cell CarcinomaActive, not recruiting

Primary Biliary CholangitisPhase 2

Active, not recruiting

Alport SyndromePhase 1/Phase 2

Active, not recruiting

Squamous Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

279 competitors in Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

20 2

Taxol

Teva

Phase 3

11 3

Tecentriq

Roche

Phase 3

6 4

Paraplatin

AAvyxa

Phase 3

19 5

Libtayo

Regeneron

Phase 3

5 6

Yervoy

Bristol-Myers Squibb

Phase 3

4 7

Vectibix

Amgen

Phase 3

3 8

Beyfortus

BeiGene

Phase 3

2 9

Gilotrif

Boehringer Ingelheim

Phase 3

10 10

Tarceva

DDutch Society of Physicians for Pulmonology and Tuberculosis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Squamous Cell Carcinoma1 trial

A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

Completed·CCalliditas Therapeutics Suisse SA·Phase 2·NCT05323656·55 enrolled

Drug Interactions1 trial

Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects

Completed·CCalliditas Therapeutics AB·Phase 1·NCT04327089·64 enrolled

Primary Biliary Cholangitis1 trial

A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

Completed·CCalliditas Therapeutics Suisse SA·Phase 2·NCT05014672·76 enrolled

Alport syndrome1 trial

A Study to Evaluate Setanaxib in Patients With Alport Syndrome

Completed·CCalliditas Therapeutics AB·Phase 1/2·NCT06274489·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Setanaxib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Setanaxib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Setanaxib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Calliditas Therapeutics Suisse SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCalliditas Therapeutics Suisse SA

Setanaxib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Squamous Cell Carcinoma1 trial

Drug Interactions1 trial

Primary Biliary Cholangitis1 trial

Alport syndrome1 trial

References

Drug Info

Quick Facts

Related News